Trial Profile

Safety and Immunogenicity Study of GSK Biologicals' Pandemic Influenza Candidate Vaccine (GSK2340272A) in Children Aged 6 to 35 Months

Status: Completed

Phase of Trial: Phase II

Latest Information Update: 25 Jul 2022

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs Influenza A virus vaccine-H1N1 (Primary) ; AS03A; AS03B
Indications Influenza A virus H1N1 subtype
Focus Adverse reactions; Pharmacodynamics
Sponsors GlaxoSmithKline; GSK

Most Recent Events

24 Nov 2010 Status changed from active, no longer recruiting to completed, according the the GlaxoSmithKline website.
28 Jun 2010 Primary endpoint `meeting or exceeding the humoral immune response criteria of the European Medicines Agency (EMA) Committee for Medicinal Products for Human Use (CHMP)' has been met.
28 Jun 2010 Results reported in Vaccine.

You need to be a logged in or subscribed to view this content

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com